Regenerative Medicine Firm RegenLab Files for Nasdaq IPO, Reports $29.3M in H1 Sales

RegenLab USA, a regenerative medicine company specializing in point-of-care cell processing devices, has filed an S-1 registration statement with the U.S. Securities and Exchange Commission (SEC) for an initial public offering. The New Jersey-based company plans to list on the Nasdaq stock market under the proposed ticker symbol RGNA.

StoneX Financial Inc. is acting as the sole book-running manager for the proposed offering. According to the filing, the company was founded by Chairman and CEO Antonino Turzi, who holds 98.64% of the voting power.

Financial Performance

The company's filing revealed significant revenue growth and a shift to profitability. For the six months ending June 30, 2026, RegenLab reported a 21% year-over-year increase in net product sales to $29.32 million.

This top-line growth translated to improved profitability:

• Operating Income: $2.1 million, compared to an operating loss of $770,000 in the same period a year prior.
• Net Income: $71,000, a notable turnaround from a net loss of $32,000 in the first half of 2025.

For the full year 2025, RegenLab generated $49.17 million in revenue but recorded a net loss of $1.24 million, which the company attributed to increased research and development expenditures. Its core biological platform accounted for over 90% of product sales in 2025, with its flagship RegenKit PRP product comprising approximately 62% of revenue.

Ad

Business and Market Strategy

RegenLab operates integrated research, development, and manufacturing facilities in New Jersey, France, and Switzerland. The company has established key distribution partnerships with industry leaders, including Stryker Corp. for the U.S. sports medicine market, Smith+Nephew in Spain, and MiMedx Group for U.S. wound care.

Its product Cellular Matrix, a device that combines platelet-rich plasma with hyaluronic acid, contributed 28.7% of revenue in 2025. The company noted it is converting its portfolio of over 70 granted patents into regulatory approvals in Europe and North America.

Regulatory Pipeline and Use of Proceeds

RegenLab recently achieved key regulatory milestones, including receiving U.S. Food and Drug Administration (FDA) 510(k) clearance for its RegenBMC bone marrow concentrate system in May 2026 and updating its EU Medical Device Regulation (EU-MDR) certification. The company is currently pursuing a modular Pre-Market Approval (PMA) from the FDA for its Cellular Matrix device for treating Grade III knee osteoarthritis.

Management plans to use the net proceeds from the IPO to expand its direct sales and marketing teams, upgrade manufacturing equipment, and fund clinical trials in Europe and the United States. Existing executives and directors have agreed to a standard 180-day lock-up period following the offering's pricing.